Study details
Enrolling now
Suvorexant and Alcohol
William Stoops
NCT IDNCT06326684ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
30
Study length
about 2.8 years
Ages
21–55
Locations
1 site in KY
About this study
This trial is testing whether suvorexant, a medication, helps reduce alcohol cravings and other related behaviors in people with Alcohol Use Disorder. The goal is to understand how orexin affects alcohol addiction in humans. This research will provide initial clinical evidence on the effects of orexin antagonism on alcohol motivation.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Alcohol
- 2.Take Placebo
- 3.Take Suvorexant
PhaseEARLY_Phase 1
DrugAlcohol
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
ethanol, suvorexant
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Blood pressure, Heart rate, Mood
Body systems
Psychiatry / Mental Health